Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021

Details

• Personal Author:
  Moline, Heidi L. ; Whitaker, Michael ; Deng, Li ; Rhodes, Julia C. ; Milucky, Jennifer ; Pham, Huong ; Patel, Kadam ; Anglin, Onika ; Reingold, Arthur ; Chai, Shua J. ; Alden, Nisha B. ; Kawasaki, Breanna ; Meek, James ; Yousey-Hindes, Kimberly ; Anderson, Evan J. ; Farley, Monica M. ; Ryan, Patricia A. ; Kim, Sue ; Nunez, Val Tellez ; Como-Sabetti, Kathryn ; Lynfield, Ruth ; Sosin, Daniel M. ; McMullen, Chelsea ; Muse, Alison ; Barney, Grant ; Bennett, Nancy M. ; Bushey, Sophrena ; Shiltz, Jessica ; Sutton, Melissa ; Abdullah, Nasreen ; Talbot, H. Keipp ; Schaffner, William ; Chatelain, Ryan ; Ortega, Jake ; Murthy, Bhavini Patel ; Zell, Elizabeth ; Schrag, Stephanie J. ; Taylor, Christopher ; Shang, Nong ; Verani, Jennifer R. ; Havers, Fiona P.
• Corporate Authors:
  CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.)Epidemic Intelligence Service. ; General Dynamics Information Technology. ; California Emerging Infections Program. ; University of California, Berkley. School of Public Health. ; Colorado. Department of Public Health and Environment. Connecticut Emerging Infections Program. ; Yale School of Public Health, New Haven, Connecticut ; Emory University School of Medicine. ; Georgia Emerging Infections Program. ; Veterans Affairs Medical Center (Atlanta, Ga.) ; Maryland. Department of Health. ; Michigan. Department of Health & Human Services. ; Minnesota. Department of Health. ; New Mexico Emerging Infections Program. ; New York State Department of Health. ; University of Rochester. School of Medicine and Dentistry. ; Ohio. Department of Health. ; Oregon Health Authority. Public Health Division. ; Vanderbilt University Medical Center. ; Salt Lake County (Utah). Health Department. ; Stat-Epi Associates, Inc.
• Description:
  What is already known about this topic? Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) have shown high efficacy in preventing symptomatic (including moderate to severe) COVID-19.
  
  What is added by this report? Among adults aged 65–74 years, effectiveness of full vaccination for preventing hospitalization was 96% for Pfizer-BioNTech, 96% for Moderna, and 84% for Janssen COVID-19 vaccines; among adults aged ≥75 years, effectiveness of full vaccination for preventing hospitalization was 91% for Pfizer-BioNTech, 96% for Moderna, and 85% for Janssen COVID-19 vaccines.
  
  What are the implications for public health practice? Efforts to increase vaccination coverage are critical to reducing the risk for COVID-19–related hospitalization, particularly in older adults.
  
  Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these vaccines have high efficacy against symptomatic disease, including moderate to severe illness (1–3). In addition to clinical trials, real-world assessments of COVID-19 vaccine effectiveness are critical in guiding vaccine policy and building vaccine confidence, particularly among populations at higher risk for more severe illness from COVID-19, including older adults. To determine the real-world effectiveness of the three currently authorized COVID-19 vaccines among persons aged ≥65 years during February 1–April 30, 2021, data on 7,280 patients from the COVID-19–Associated Hospitalization Surveillance Network (COVID-NET) were analyzed with vaccination coverage data from state immunization information systems (IISs) for the COVID-NET catchment area (approximately 4.8 million persons). Among adults aged 65–74 years, effectiveness of full vaccination in preventing COVID-19–associated hospitalization was 96% (95% confidence interval [CI] = 94%–98%) for Pfizer-BioNTech, 96% (95% CI = 95%–98%) for Moderna, and 84% (95% CI = 64%–93%) for Janssen vaccine products. Effectiveness of full vaccination in preventing COVID-19–associated hospitalization among adults aged ≥75 years was 91% (95% CI = 87%–94%) for Pfizer-BioNTech, 96% (95% CI = 93%–98%) for Moderna, and 85% (95% CI = 72%–92%) for Janssen vaccine products. COVID-19 vaccines currently authorized in the United States are highly effective in preventing COVID-19–associated hospitalizations in older adults. In light of real-world data demonstrating high effectiveness of COVID-19 vaccines among older adults, efforts to increase vaccination coverage in this age group are critical to reducing the risk for COVID-19–related hospitalization.
  
  Suggested citation for this article: Moline HL, Whitaker M, Deng L, et al. Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021. MMWR Morb Mortal Wkly Rep. ePub: 6 August 2021.
  
  mm7032e3.htm?s_cid=mm7032e3_w
  
  mm7032e3-H.pdf
  
  
• Subjects:
  Aged CoronaVirus Infections COVID-19 COVID-19 Vaccines Hospitalization Risk Assessment Treatment Outcome Vaccination Coverage Vaccines, Synthetic
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Name as Subject:
  COVID-NET ; Janssen COVID-19 vaccine ; Moderna Covid-19 Vaccine ; Pfizer-BioNTech COVID-19 Vaccine
• Place as Subject:
  California ; Colorado ; Connecticut ; Georgia ; Maryland ; Michigan ; Minnesota ; New Mexico ; New York ; Ohio ; Oregon ; Tennessee ; Utah
• Pages in Document:
  6 pdf pages
• Volume:
  70
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:9c37570eb708cb81a15089ffb43696f18f4fc80221f3044ed56b32f2df81e9b98a34acdcbdf214098e26a47ac271291c807d44f71372cdca74c8d28d96cd863a
• Download URL:
  https://stacks.cdc.gov/view/cdc/108654/cdc_108654_DS1.pdf
• File Type:
  [PDF - 573.34 KB ]